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When blood clots, elastase is released from granulocytes, which has fibrinolytic
properties and which can probably digest fibrin deposits in areas of inflammation
where coagulation may occur and granulocytes accumulate (1-4). In addition, this
elastase e can inactivate coagulation factor IX (5, 6), fibronectin (7) a2-antiplasmin
and C1-inhibitor (8) by proteolytic cleavage. It is therefore probably capable of
modifying hemostatic responses particularly in the presence of inflammation.
High molecular weight kininogen (HMW kininogen)' promotes blood coagula-
tion (9-12) and can serve as a source of vasoactive polypeptides that can produce
some of the components of the inflammatory response. Plasma from persons with
an hereditary deficiency ofHMWkininogen is severely deficient in coagulant prop-
erties attributable to thisprotein, and contact-initiated generation offibrinolytic ac-
tivity in this plasma is markedly impaired (9-12). Nonetheless, individuals withthis
hereditary deficiency do not have a hemorrhagic or an identifiable thrombotic dis-
order. Since bradykinin, avasoactive peptide that can induce vasodilation, enhance
vascular permeability, and cause pain, is part ofthe HMWkininogen molecule and
can be released from the kininogen either by plasma kallikrein or plasmin (13-16),
it was important to determine ifgranulocytes, which accumulate in areas ofinflam-
mation, couldalso releasekininas aresult ofcleavage ofHMWkininogenby granulo-
cyteelastase. The followingexperiments show that apreparation ofgranulocyte elastase
cleaved purified human HMW kininogen into multiple low molecular weight frag-
ments and destroyed its clot-promoting activity, but did not release kinin from the
molecule.
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Materials and Methods
Benzamidine and polyacrylamide were obtained from Eastman Kodak Company, Roch-
ester, NY; Polybrene (hexadimethrine bromide) and trisodium EDTA were obtained from
Aldrich Chemical Co., Milwaukee, Wl. QAE Sephadex A-50, SP Sephadex C-50, DEAE-
Sephadex A-50, and cyanogen bromide-activated Sepharose were all obtained from Phar-
macia Fine Chemicals, Piscataway, NJ. DE-23 (diethylaminoethyl cellulose) was obtained
This work was supported by grant HL-15690 from the United States Public Health Service and the
Children's Hospital Research Foundation. Address correspondence to Virginia H. Donaldson, Chil-
dren's Hospital Research Foundation, Elland and Bethesda Avenues, Cincinnati, OH 45229.
1 Abbreviations used in this paper: HMW, high molecular weight; NHP, normal human plasma; TBS,
Tris buffered saline.
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from Whatman, Ltd., Springfield Hill, Kent, UK. a,-antitrypsin was obtained from
Calbiochem-Boehring Corp., LaJolla, CA (lots No. L. 101296 and 701049). These prepara-
tions contained MIMI a,-antitrypsin when examined in an isoelectric focussing technique
in PAGE. Soybean trypsin inhibitor, SDS, and molecular weight markers were from Sigma
Chemical Co., St. Louis, MO; diethylstilbestrol was from Eli Lilly, Indianapolis, IN; Cen-
trolex O phospholipids was a gift from Central Soya, Chicago, Illinois; kaolin came from
Fisher Scientific Co., Norwood, Ohio. Bradykinin came from Schwarz-Mann, Orangeburg,
NY, and crystalline bovine serum albumin came from Pentex, Kalamazoo, Michigan. All
chemical reagents were of analytical grade. Elastase purified from human sputum was from
Elastin Products Company, Pacific, MO (lot SES63).
Buffers used in test mixtures are noted in the legends; barbital-saline buffer, pH 7.4, was
used in coagulation assays and contained 2.76 gm of barbital, 2.06 gm of sodium barbital,
and 7.3 gm of sodium chloride/liter.
HMW kininogen was isolated from human plasma by modifications (16) ofpreviously pub-
lished procedures (17). This preparation gave a single homogeneous band when analyzed
in SDS-PAGE (see Fig. 1), except where noted (see Fig. 4). Humanplasma kallikrein was iso-
lated from acetone-treated plasma according to the procedure described by Nagase and Bar-
rett (18) and modified in repeating the affinity chromatography of the kallikrein on Sepharose-
4B-soybean trypsin inhibitor column afterremoving IgG by immunoaffinity chromatography.
It had a specific activity of 57 coagulation U/mg of protein, measured in an assay testing
its ability to shorten the activated partial thromboplastin time (19, 20) of plasma from an
individual with a severe inherited deficiency of plasma prekallikrein (21). To measure kal-
likrein coagulant activity, a 1 min incubation period, instead of 8 min, was carried out before
recalfication of test mixtures. Clot-promoting activity of HMW kininogen or its derivatives
was measured with a modified activated partial thromboplastin time (19, 20) using a kininogen
deficient plasma (12) as substrate. The coagulant property attributable to HMW kininogen
or plasma kallikrein was quantified by comparing the shortening of the clotting time of
kininogen deficient, or prekallikrein-deficient plasma by the test samples with the shortening
achieved by identical dilutions of pooled normal human plasma (NHP), arbitrarily defined
to have 1 U of activity per ml of plasma, or of purified untreated HMW kininogen. The
comparisonwas made using a linear double logarithmic plot of the clotting time vs. the amount
of normal plasma or kininogen used .
PAGE was performed in a 0.75-mm thin slab vertical Hoeffer apparatus containing 7 .5%
gel and 0.1% SDS. Samples were incubated at 100°C for 90 s after addition of SDS. Elec-
trophoresis was carried out at pH 8.6 in a Tris (0.025 M) glycine (0.192 M) buffer, according
to the method of Laemmli (22) and using gels with a continuousconcentration of 7.5 % poly-
acrylamide. Reduced mixtures were prepared by adding 2-ME in an amount to give a final
concentration of 2.5% before adding SDS to give a final concentration of 1%.
Kinin activity was measured by applying test samples to an estrus rat uterus suspended
in dejalon's solution at pH 7.4 (23) in an 8-ml organ bath maintained at 30°C . Varied amounts
ofsynthetic bradykininwere used as standards for comparison ofthe amount ofkinin activity
in test fractions. The comparison was made by measuring the time required for the onset
of contraction ofthe isometric muscle after the injection of the standard or test samples into
the organ bath. The times were then plotted against the amount of synthetic bradykinin used
on a semilogarithmic plot, and test samples were compared with this linear plot according
to the times of onset of contractions induced by each sample.
Protein concentrations were estimated by reading the OD of solutions at 280 mn with a
Gilford 240 spectrophotometer (model 240, Gilford Instrument Laboratories, Inc., Oberlin,
OH) and comparing the readings to those of a solution ofcrystalline BSA. All protein prepa-
rations were dissolved in 0.05 M Tris, pH 7.4, and 0.15 M NaCl. The same buffer was used
in test mixtures during incubation.
Results
To assess the effect of elastase upon HMW kininogen, 0.02, 0.06, or 0.18 ug of
elastase was incubated with 21 gg of purified human HMW kininogen at 37°C. AfterKLENIEWSKI AND DONALDSON
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FIGURE 1 .
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(A) SDS-PAGE ofHMW kininogen digested by elastase under nonreducing condi-
tions . HMW kininogen, 0.05 ml (420 ug/ml), was incubated for 15 min at 37°C with 0.01 ml
of elastase at a concentration of 2 ug/ml (lane 1), 6 gg/ml (lane 2), and 18 ug/ml (lane 3). These
mixtures, as well as control samples containing 5 ttg of elastase (lane 4) and 0.05 ml ofHMW
kininogen containing 5 wg of protein (lane 5), were made to 10% in SDS, placed in a 100°C
boiling water bath for 90 s, and then run at 7 .5% SDS-PAGE . The positions of the bands of
molecular weight standards (not included in this photo) are noted at the left . (B) The same ex-
periment was performed under reducing conditions using 10% in SDS and 2.5% p-ME .
15 min at 37°C, samples of each incubation mixture were mixed with SDS, heated
to 100°C for 90 s, and then subjected toPAGE . Multiple low molecular weight cleavage
fragments evolved during digestion with as little as 0.02 Ag of elastase (Fig . 1, lane
1), having molecular weights of from 40,000 to 110,000 . In other experiments, after
only 2 min of incubation, multiple low molecular weight components of the HMW
kininogen were visible after electrophoresis under nonreducing conditions . When
examinedunder reducing conditions, six fragments ofHMW kininogen, all having
molecular weights of60,000 and less, were apparent after 40min ofincubation (Fig.
1, and Fig. 2, top) . Therefore, HMW kininogen was extensively digested by granulo-
cyte elastase .
Effect of Digestion on Kinin Release.
￿
When HMW kininogen was incubated with
granulocyte elastase and samples applied to an isolated estrus rat uterus during the
digestion period, there was no contraction of the isolated muscle (Table 1, lines 3
and 4) . When the digests were then exposed to a preparation ofhuman plasma kal-
likrein, kinin activity evolved rapidly in an amount equal to that released by the
kallikrein from HMW kininogen not previously digested by elastase (Table I, line
5) . The absence of kinin activity from these incubation mixtures was not due to the
destruction of the kinin by elastase, for the elastase failed to inactivate synthetic
bradykinin (Table I, lines 6 and 7) .
To determine if elastase digestion might have enhanced the rate of later release
of kinin from HMW kininogen by plasma kallikrein, 42 gg of HMW kininogen
was incubated with elastase (3 pg) for 30 min at 37°C, or with buffer for the same
period, and the rates at which kinin activity was then released in each mixture by1898 GRANULOCYTE ELASTASE CLEAVES HUMAN KININOGEN
FIGURE 2 .
￿
The digestion ofHMW kininogen by elastase and decay of its clot-promoting ac-
tivity. HMW kininogen, 0.45 ml (210 pg/ml), was mixed with 0.05 ml of elastase (10 pg/ml) in
TBS . After incubation at 37°C for the times noted, 0.04 ml samples were made to 10% in SDS
or 10% in SDS and 2 .5% in p-ME and were analyzed on 7.5% SDS-PAGE after 90 s at 100°C
(lanes 1-6, respectively) . Lane 7 contained a control sample of 5 pg of elastase, and lane 8, 3
pg of control HMW kininogen . For coagulation studies (lower panel), 0.01 samples of the same
kininogen mixtures were tested at times noted on the abscissa for their ability to correct the acti-
vated partial thromboplastin time of kininogen deficient plasma after being diluted 1:20 in bar-
bital saline buffer, pH 7.4. The graph shows the percent of initial HMW kininogen coagulation
activity found in the same incubation mixtures in the presence (") or absence (O) of elastase .
The upper panels illustrate SDS-gel electrophoresis of the samples containing elastase carried
out at the times of incubation indicated (top), under nonreducing (left paned) and reducing (right)
conditions .
a preparation of plasma kallikrein were compared . In this experiment, there was
no enhancement, but a minor reduction in the amount of kinin activity released
by the kallikrein in the mixture containing elastase-treatedHMW kininogen (Fig . 3) .
Effect of Granulocyte Elastase on Clot-promoting Activity ofHMWKininogen .
￿
The do-
main of theHMW kininogen molecule responsible for its clot-promoting activity
is in the light chain and is distinct from the kinin-containing region (24-27) . ToTest mixtures
KLENIEWSKI AND DONALDSON
TABLE I
Elastase Does not Release Kinins from HMW Kininogen and
Does not Destroy Bradykinin
HMW kininogen (60 4g/ml) + buffer
HMW kininogen + kallikrein (5 vg/ml)
HMW kininogen + elastase (5 wg/ml)
HMW kininogen + elastase (50 ug/ml)
HMW kininogen + elastase (50 ug/ml)
+ 25°C x 30 min with kallikrein (5 ug/ml)
Bradykinin (100 ng/ml) + Buffer
Bradykinin (100 ng/ml) + Elastase (20 vg/ml)
Kinins released
from 1 .0 ml of
HMW kininogen
n8
0
440
0
0
440
Kinins
ng/ml
100
100
After incubation of the mixtures, shown in the left column, containing 22 ug
of HMW kininogen, samples of each mixture were tested for kinin activity
on an isolated estrus rat uterus . The enzyme was neutralized with soybean
trypsin inhibitor before this assay. In the last experiment of the upper panel,
HMW kininogen was first incubated with elastase, and then with kallikrein,
to determine if elastase destroyed the bradykinin sequence. The experiment
shown in the lower panel tested the effect of elastase on synthetic bradykinin
alone. Incubations were carried out in 0.05 M TBS (0.15 M), pH 7.4.
Incubated at 25°C for 30 min.
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test the effect of granulocyte elastase upon the clot-promoting property of HMW
kininogen, elastase in amounts of 0.02-0.64 ttg was incubated with each ml of ei-
ther normal plasma or of purified HMW kininogen (95 gg) . Then, the specific clot-
promoting activity attributable to HMW kininogen was quantified by measuring
the effects ofdilutions of these incubation mixtures upon the clotting time of plasma
from a person with a severe hereditary deficiency of plasma kininogens (12). The
specific HMW kininogen clot-promoting activity of normal plasma was decreased
when it had been incubated with 0.08-0.64 ug/ml of elastase (Table II, lines 1-6).
When purified HMW kininogen was incubated with as little as 0.03 wg/ml of elastase,
its specific clot-promoting activity was destroyed (Table II, lines 7-10). The differ-
ence in the sensitivity of the kininogen to elastase digestion in the purified mixture
as contrasted to that of plasma probably mainly reflects the inhibition of the elastase
by al-antitrypsin in plasma (28); there was no al-antitrypsin in the mixture con-
taining purified HMW kininogen. The rate of destruction of the clot-promoting ac-
tivity of the HMW kininogen is illustrated in Fig. 2 (bottompaneo, and the fragmen-
tation ofthe molecule during this incubation is shown in the SDS gel electrophoretic
patterns in the upper panel. It is clear that coagulant activity was readily lost as
fragmentation of the molecule occurred.
Effect of Purified at An11trypsIn upon Digestion ofHMWKininogen by Elastase.
￿
Since
al-antitrypsin is an elastase inhibitor in NHP (28), its effect on the destruction of
HMW kininogen clot-promoting activity by elastase was measured. The loss of clot-
promoting activity was prevented only when equimolar or greater amounts of al-1900
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15
￿
30
￿
45
Incubation time (min.)
r-i HMW-kininogen 4 kallikrein
HMW-kininogen+elastase+kallikrein
--+ HMW-kininogen+kallikrein
preincubated
with elastase
o--o HMW-kininogen+buffer
HMW-kininogen+elastase
FicURI: 3.
￿
The rate of kinin release by kallikrein from HMW kininogen during digestion by
elastase. HMW kininogen, 0.2 ml (210 ug/ml), was incubated for 10 min at 37°C alone or with
0.05 ml of elastase (60 ug/ml). Then, at 0 min, 0.05 ml of kallikrein (1.2 ug/nil) (0) or 0.05 ml
elastase (A) (60 ug/ml) or both kallikrein and elastase (A) was added to the kininogen which
had first been incubated alone, as indicated, and the volumes adjusted to 0.5 ml with buffer.
Kallikrein was added to the kininogen already incubated with elastase (/). During the second
incubation at 22°C, samples were tested for the amount of kinin released at the times noted on
the abscissa. All reagents were in TBS, pH 7.4. Kinin activity was quantified as described in
the Materials and Methods section.
antitrypsin had been incubated with elastase before HMW kininogen was added
to the mixture (Table III).
When at-antitrypsin was added to mixtures of purified HMW kininogen and
elastase that had already been incubated together for 45 min, the kininogen was
extensively digested (Fig. 4 A), indicating that digestion occurred before electropho-
resis in SDS. In less than equimolar amounts, the at-antitrypsin failed to prevent
digestion of HMW kininogen (Fig. 4 B), or loss of its clot-promoting activity (Table
III). Suboptimal amounts of al-antitrypsin partially impaired HMW kininogen
digestion by elastase (Fig. 4 B, lanes 4 and 5), and equimolar amounts prevented
its cleavage (Fig. 4 B, lanes 6 and 7). The bands of -84,000 molecular weight in
lanes 6-9 probably represent complexes between elastase (32,000) and at-antitrypsin
(52,000) (Fig. 4 B).
Since we had noted that the clotting times of unincubated test mixtures containing
HMW kininogen and at-antitrypsin were often longer than those of mixtures con-
taining buffer in place of inhibitor, the effect of al-antitrypsin upon the clotting of
normal plasma was assessed. When ai-antitrypsin was added to normal human
plasma the clotting time of the plasma was delayed (Table IV). In this experiment,
the amount of ai-antitrypsin added represented an increase of 30-60% in the levelsKLENIEWSKI AND DONALDSON
TABLE II
Effect of Elastase Incubation on HMW Kininogen Clot-promoting Activity
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NHP or purified HMW kininogen, 0.03 ml (420 vg/ml), was mixed either with 0.01 ml of Tris buffered
saline, pH 7.4, or 0.01 ml of elastase at a concentration of 16 vg/ml. After a 15-min incubation at 37°C,
mixtures were mixed with 1 .2 ml ofthe barbital saline at 0°C and immediately tested for specific clot-promoting
activity attributable to HMW kininogen (lines 1-8) by measuring the effect of each mixture on the clotting
time o£ plasma from an individual with an inherited deficiency of kininogens (see Materials and Methods).
In the experiments shown in lines 9-10, elastase was added to purified HMW kininogen at 0°C after incuba-
tion of the kininogen, and the mixture was immediately tested for coagulant activity. In the experiment,
shown in lines 11 and 12, the HMW kininogen and elastase were incubated together for 15 min at 37°C
before the mixture was tested for coagulant activity.
of plasma al-antitrypsin, assuming that the concentration in normal plasma is be-
tween 1.5 and 3.5 mg/ml (29).
Discussion
Although purified HMW kininogenwascleaved into multiple low molecularweight
fragments by purified human granulocyte elastase (Fig. 1, A and B), kinin activity
was not released in the process, norwas domain of the kininogen molecule containing
the kinin sequence destroyed (Table I). Moreover, thecleavage products, which were
mainly of molecular weights of 60,000 and less, still contained the kinin sequence
that could be released when these fragments were incubated with plasma kallikrein.
These experiments do not determine if the kinin activity was due to the nonapep-
tide, bradykinin, or to one of the larger peptides that may be released by proteases
and have kinin activity. While one cannot directly extrapolate from these results to
an in vivo situation, these events could conceivably provide low molecular weight
forms of kininogen as a source of kinin in areas of inflammation.
It is possible that elastase might regulate the generation of clot-promoting ac-
tivity in part through its destruction of the clot-promoting properties of HMW
kininogen (Table II, Fig. 2) . Since the structures required for clot-promoting ac-
tivity of HMW kininogen reside in the light chain of the molecule (24) and factors
XI or prekallikrein or kallikrein can form complexeswith the light chain (25), these
critical regions may be digested by elastase. The histidine-rich region of the light
chain, which is apparently responsible for binding of HMW kininogen to kaolin
Test mixtures
Elastase final
concentration Clotting time
ug/ml s
1 . Buffer + NHP 0 85
2 . Elastase + NHP 0.64 110
3 . Elastase + NHP 0.32 102
4. Elastase + NHP 0.08 88
5 . Elastase + NHP 0.04 86
6. Elastase + NHP 0.02 83
7 . Buffer + kininogen-deficient plasma 0 > 300
8. Purified HMW kininogen + kininogen-deficient plasma 0 85
9. Purified HMW kininogen + elastase added
10. after incubation at 37°C for 15 min 0.03 86
11 . Purified HMW kininogen + elastase added
12 . before incubation for 15 min at 37°C 0 .03 >3001902 GRANULOCYTE ELASTASE CLEAVES HUMAN KININOGEN
FIGURE 4.
￿
(A) Elastase (0 .5 Irg) was incubated withHMW kininogen for 0 min (lanes 2 and
7) and 45 min (lanes 3 and 8) and an equimolar amount (1.0 ug) of a,-antitrypsin was added
at the conclusion ofthe incubation period, beforeSDSwas added (lanes 4and9).HMW kininogen
incubated with buffer is in lanes 1and6; lane 5 is blank . Electrophoretic analysis wasdone under
nonreducing (NR) (lanes 1-4) and reducing (R) (lanes 6-9) conditions . Ahigh molecular weight
standard protein mixture is in lane 10 . The elastase was added to 0-min mixtures after SDS
and 2-ME (lanes 2and 7). (B) High molecular weight kininogen(HK) was incubated in buffer
for 45 min (lane 1), with 0.5 wg of elastase (E/I = -, lanes 2 and 3), or with elastase that had
already been incubated with a,-antitrypsin at 37°C for 10 min (lanes 4-7) . The molar ratios of
theenzyme to inhibitor in the incubation mixtures was 20 :1 (lanes 4 and5) or 1:1 (lanes 6and
7), and no inhibitor was present in the mixture shown in lanes 2 and 3 . The mixtures in lanes
8 and 9 contained equimolaramounts of enzyme and inhibitor, but no high molecular weight
kininogen .Hrepresents high molecular weight standard marker proteins that hadbeen reduced
in each instance . PAGE was run under nonreducing (left) and reducing (sight) conditions . M .
x 10-3 are shown on the right .
(26, 27), may have been digested, for kaolin was used in the assay to measureHMW
kininogen coagulant activity . These studies do not define the points ofelastase cleavage .
It is possible that all of these regions have been cleaved .
When blood clots, the elastase concentration in the fluid phase is increased >10-
fold (1), presumably reflecting the release of this enzyme from granulocytes either
because of a secretory or a lytic event (30) . Once this has occurred, the elastase in
plasma is readily inhibited by al-antitrypsin (28, 31, 33) and can also interact with
a2-macroglobulin (33) . In the present studies, the blockade of digestion of the
kininogen with purified at-antitrypsin supports the likelihood that the effective en-
zymatic activity is elastase . In subjects deficient in at-antitrypsin, the pulmonary
and hepatic pathologic changes that occur as a result ofthe deficiencymay be largely
due to elastase activity (31, 32) . The ability ofelastase to inactivate coagulation factorKLENIEWSKI AND DONALDSON
TABLE III
Effect of al-Antitrypsin (aIAT) upon Elastase-induced Destruction
of Clot-promoting Activity of HMW Kininogen
HMW kininogen, 12.6 pg in 0.03 ml, was added to the mixtures containing 0.01 ml of'
elastase and/or ajAT (left column) that had been incubated together at 37° for 5 min and in-
cubation continued for another 15 min . Samples from each mixture were then diluted four-
fold in cold barbital saline buffer and tested for clot-promoting activity attributable to HMW
kininogen by the procedure described in Materials and Methods .
* 37°C for 5 min.
IX (5, 6) and HMW kininogen clot-promoting activity raises the possibility that
it could regulate the generation of clot-promoting activity in vivo that might be ini-
tiated by the activation ofHageman factor, by altering interactions promoting coagu-
lation directly through the "intrinsic" coagulation pathway and possibly by affecting
mechanisms by which factor VII activity is markedly enhanced by factors IXa and
Xa in vitro (34-37). "Elastase-like" proteases from granulocytes may inactivate coagu-
lation factors VIII, XII, V, and XIII (38), but it is not clear that all of these factors
were inactivated by elastase in these preparations.
The prolongation of the clotting time ofnormal plasma, which was observed when
this al-antitrypsin was added to the plasma (Table IV), may reflect its inhibition
of factor XIa, which was reported earlier (39). It is important to note that the at-
antitrypsin used in these experiments was in type M1M1 upon analysis by an isoelectric-
focussing technique because Z type al-antitrypsin has a lower association constant
for leukocyte elastase than the M1M1 forms of the inhibitor (40).
TABLE IV
Effect of al-Antitrypsin upon the Clotting Time of Normal Plasma
Normal plasma was incubated with an equal volume ofeither barbital saline buffer
or of a solution ofai-antitrypsin containing either 25 or 50 pg ofthis inhibitor,
plus phospholipid and kaolin at 37°C for 8 min. Calcium chloride was then added
and the clotting times (21, 22) of the mixtures were recorded, each of which
represents the mean of duplicate mixtures.
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Specific HMW kininogen
Incubation mixtures* clotting times
Buffer + HMW kininogen
s
85
Elastase, (0.64 pg) + HMW kininogen >300
ajAT (1 .6 pg) + Elastase (0.64 pg) + HMW kininogen 85
aiAT (0.8 vg) + Elastase (0.64 pg) + HMW kininogen 120
aiAT (0.4 pg) + Elastase (0.64 ug) + HMW kininogen 250
aiAT (0.2 pg) + Elastase (0.64 og) + HMW kininogen >300
aiAT (1 .6 pg) + Buffer 86
Test mixture Clotting time
Normal plasma + buffer
s
96
Normal plasma + al-AT, 25 gg III
Normal plasma + al-AT, 50 Vg 1191904
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Granulocyte elastase is a "neutral" serine protease and a glycoprotein having a
molecular weight of -30,000 (41). Although it has a pH optimum of 8.5 against
most of its substrates (41), in the present studies, proteolysis was readily achieved
at pH 7.4. Therefore, granulocyte elastase could function under physiologic condi-
tions of pH in vivo.
The fibrinolytic potential of granulocytes has been known since the beginning of
this century (42, 43). The fibrinolytic property of granulocyte elastase may be one
of its most significant contributions to reactions that may occur in the body during
injury or inflammation. Elastase can inactivate a2-antiplasmin (8). The release of
leukocyte elastase leading to fibrinolysis occurs in a calcium dependent reaction (1),
and the enzyme can then release a fibrinogen fragment D cleavage product, which
has been shown to be immunologically distinct from plasmin-generated fragment
D (30). Therefore, elastase proteolysic activity is distinct from that of plasmin.
Moreover, elastase can inactivate C1-inhibitor (8), which can regulate the first com-
ponent of complement (44) and is one of the plasma inhibitors that can impair the
actions ofplasmin (45), coagulation factors XIIa, XIa, and kallikrein (45-47). Elastase
can also alter the function of a-thrombin (48), and may therefore add a critical dimen-
sion to altered hemostasis and effective fibrinolytic activity which may evolve in areas
of inflammation involving both elastase and plasmin. It has been reported that the
release of the granulocyte elastase can occur when granulocytes are aggregated by
plasma kallikrein (49), since the release of elastase from granulocytes in prekallikrein-
deficient plasma was impaired (49). When prekallikrein-deficient plasma was diluted,
however, release of elastase from granulocytes in this plasma was similar to its re-
lease in granulocytes suspended in normal plasma (30). Therefore, substances other
than prekallikrein must be important in this process. Thrombin does not directly
release elastase from granulocytes (1), but events involving the Hageman factor de-
pendent generation ofclot-promoting activity are probably important in its release.
The physiologic mechanisms of elastase generated fibrinolysis are not yet clearly
defined.
Summary
Purified human granulocyte elastase cleaved purified human high molecular weight
(HMW) kininogen into multiple low molecular weight fragments, and destroyed
the clot-promoting activity of the HMW kininogen. Elastase digestion did not re-
lease kinin or destroy the bradykinin portion ofthe HMW kininogen molecule; kal-
likrein could release kinin from the elastase-induced low molecular weight digestion
products of HMW kininogen. Purified a}-antitrypsin prevented the destruction of
the clot-promoting activity of HMW kininogen by elastase; it also delayed the clot-
ting of normal plasma. Elastase may play a significant role in altered hemostasts
as well as fibrinolysis, in areas of inflammation to which polymorphonuclear leuko-
cytes have been attracted.
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